Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

RUFUS - Group Rumination-focused CBT for Negative Symptoms

RUFUS - a Randomized Mixed Methods Pilot Clinical Trial Investigating the Relevance and Feasibility of Rumination-focused Cognitive Behavioral Therapy in the Treatment of Patients With Emergent Psychosis Spectrum Disorder

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Abstract - -- Introduction: Psychosis spectrum disorders are characterized by both positive and negative symptoms, but whereas there is good effect of treatment on positive symptoms, there is still a scarcity of effective interventions aimed at reducing negative symptoms. Rumination has been proposed as an important and fundamental factor in the development and maintenance of symptoms across psychiatric diagnoses, and there is a need to develop effective interventions targeting rumination behaviors and negative symptoms in patients with psychotic disorders. The aim of the current study is to investigate the feasibility and acceptability of group rumination-focused cognitive behavioral therapy (RFCBT) in the treatment of young people with psychosis spectrum disorders as well as investigating potential indications of treatment efficacy. Methods and analysis: The study is a mixed-method clinical randomized controlled pilot trial with a target sample of 60 patients, who are randomized to either receive 13 weeks of group CFCBT or 13 weeks of treatment as usual (TAU). All patients are examined at the start of the project and at the 13-week follow-up. The researcher will compare changes in outcomes from baseline to posttreatment between group CFCBT and TAU. In addition, qualitative analyzes are carried out to explore feasibility and acceptability and to uncover the patients' experience of receiving the intervention.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Diagnosed with a psychosis spectrum disorder (ICD-10 F2x) 2. At least 8 months left of their OPUS treatment 3. The presence of rumination behavior as assessed by a score of minimum 30 on the Perseverative Thinking Questionnaire (PTQ) 4. Danish-speaking Who Should NOT Join This Trial: 1. Substance abuse or positive symptoms that make participation in therapy difficult 2. Severe suicidal thoughts/behavior 3. Lacks capacity to consent 4. Mild, moderate, or severe intellectual disability (IQ ˂ 70) 5. Planned adjustment of antidepressant and/or antipsychotic treatment (noted in the patient's medical record) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Diagnosed with a psychosis spectrum disorder (ICD-10 F2x) 2. At least 8 months left of their OPUS treatment 3. The presence of rumination behavior as assessed by a score of minimum 30 on the Perseverative Thinking Questionnaire (PTQ) 4. Danish-speaking Exclusion Criteria: 1. Substance abuse or positive symptoms that make participation in therapy difficult 2. Severe suicidal thoughts/behavior 3. Lacks capacity to consent 4. Mild, moderate, or severe intellectual disability (IQ ˂ 70) 5. Planned adjustment of antidepressant and/or antipsychotic treatment (noted in the patient's medical record)

Treatments Being Tested

OTHER

group rumination focused cognitive behavioural therapy

Psychotherapy

OTHER

Treatment as usual

opus treatment

Locations (1)

Mental Health Centre Copenhagen
Copenhagen, Denmark